%0 Journal Article
%T Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer
%A Akseli Hemminki
%A Anna Kanerva
%A Anniina Koski
%A Ilkka Liikanen
%A Lotta Vassilev
%A Mikko Siurala
%A Minna Oksanen
%A Raita Heiskanen
%A Sari Pesonen
%A Simona Bramante
%A Tiina Hakonen
%A Timo Joensuu
%J Archive of "Oncoimmunology".
%D 2016
%R 10.1080/2162402X.2015.1078057
%X Breast cancer is a heterogeneous disease, characterized by several distinct biological subtypes, among which triple-negative breast cancer (TNBC) is one associated with a poor prognosis. Oncolytic virus replication is an immunogenic phenomenon, and viruses can be armed with immunostimulatory molecules to boost virus triggered antitumoral immune responses. Cyclophosphamide (CP) is a chemotherapy drug that is associated with cytotoxicity and immunosuppression at higher doses, whereas immunostimulatory and anti-angiogenic properties are observed at low continuous dosage. Therefore, the combination of oncolytic immuno-virotherapy with low-dose CP is an appealing approach
%K Breast cancer
%K combination therapies
%K cyclophosphamide
%K GM-CSF
%K oncolytic adenovirus
%K oncolytic virotherapy
%K triple-negative breast cancer
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4801445/